Shares of Nuformix plc (LON:NFX – Get Free Report) rose 18.8% on Friday . The company traded as high as GBX 0.06 ($0.00) and last traded at GBX 0.06 ($0.00). Approximately 47,841,488 shares were traded during trading, an increase of 195% from the average daily volume of 16,233,574 shares. The stock had previously closed at GBX 0.05 ($0.00).
Nuformix Stock Up 20.8 %
The firm has a 50-day moving average of GBX 0.05 and a two-hundred day moving average of GBX 0.11. The company has a quick ratio of 3.35, a current ratio of 1.12 and a debt-to-equity ratio of 1.17. The stock has a market capitalization of £475,199.80, a price-to-earnings ratio of -1.63 and a beta of 1.22.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Read More
- Five stocks we like better than Nuformix
- What Are Dividend Achievers? An Introduction
- EV Sales Are Hitting Record Highs: 3 ETFs That Can Benefit
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Reasons Palo Alto May Be the Best Cybersecurity Stock in 2025
- How to Invest in Biotech Stocks
- ServiceNow Targets New Highs With AI and Automation
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.